The antagonic behavior of GPIHBP1 between EAT and circulation does not reflect lipolytic enzymes levels in the tissue and serum from coronary patients

• Published in: Clinica chimica acta Vol. 510; pp. 423 - 429
• Main Authors: Barchuk, Magalí, Nagasawa, Takumi, Murakami, Masami, López, Graciela, Baldi, Julio, Miksztowicz, Verónica, Rubio, Miguel, Schreier, Laura, Nakajima, Katsuyuki, Berg, Gabriela
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2020
• Subjects: Adipose Tissue; Coronary Artery Disease; Endothelial lipase; Epicardial adipose tissue; Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein-1; Humans; Lipoprotein Lipase; Receptors, Lipoprotein; Endothelial lipase; Lipoprotein lipase; Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein-1; Epicardial adipose tissue
• ISSN: 0009-8981; 1873-3492
• DOI: 10.1016/j.cca.2020.08.001

•Circulating LPL concentration is lower in CABG patients, without differences in EAT.•Circulating EL concentration is higher in CABG patients, without differences in EAT.•GPIHBP1 levels are lower in serum, and higher in EAT, from CABG patients.•Serum ApoCII levels are higher in CABG patients, while ApoCIII levels are unchanged.•In serum, LPL and EL concentrations are inversely correlated. Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. Recently, triglyceride rich lipoproteins are proposed to contribute to CAD risk; its concentrations would be partly determined by lipoprotein lipase (LPL) and endothelial lipase (EL). Epicardial adipose tissue (EAT), a visceral AT surrounding myocardium and coronary arteries, emerged as an important actor in CAD; the increase in its volume could be a consequence of LPL and EL. Circulating enzymes levels would be conditioned by local tissue factors. Our aim was to evaluate LPL, EL and their regulators levels in serum and EAT from CAD patients, searching for possible parallelisms and their role in the lipoprotein profile. In serum, EAT and subcutaneous AT (SAT) from patients undergoing coronary artery bypass graft (CABG, n = 25) or valve replacement (No CABG, n = 25), LPL, EL and glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein-1 (GPIHBP1) expression were evaluated. Besides, Apoprotein (Apo)CII, CIII and AV were determined in serum, along with lipoprotein profile. Insulin-resistance markers were higher in CABG (p < 0.05). Serum LPL levels were decreased (p = 0.045), while EL levels increased (p < 0.001) in CABG, without differences in EAT or SAT. Circulating GPIHBP1 concentrations were decreased in CABG (p = 0.047), while EAT GPIHBP1 expression was increased (p < 0.001). ApoCII and ApoAV concentrations were higher in CABG (p = 0.016 and p = 0.047, respectively), without differences in ApoCIII concentrations between groups. In EAT, LPL and EL protein levels were not changed in CAD, although GPIHBP1 protein levels were higher. EAT would be a minor contributor to the circulating levels of the enzymes.